ARTICLE IN PRESS



Keywords:

ARTICLE IN PRESS

W. King et al. / Surgery for Obesity and Related Diseases 1 (2017) 00-00

or marijuana), and SUD treatment (counseling or hospitalization for alcohol or drugs) presurgery and annually postsurgery for up to 7 years through January 2015. **Results:** Of 2348 participants who underwent RYGB or LAGB, 2003 completed baseline and follow-up assessments (79.2% women, baseline median age: 47 years, median body mass index 45.6). The year-5 cumulative incidence of postsurgery onset AUD symptoms, illicit drug use, and **(3** SUD treatment were 20.8% (95% CI: 18.5–23.3), 7.5% (95% CI: 6.1–9.1), and 3.5% (95% CI: 2.6–4.8), respectively, post-RYGB, and 11.3% (95% CI: 8.5–14.9), 4.9% (95% CI: 3.1–7.6), and .9% (95% CI: .4–2.5) post-LAGB. Undergoing RYGB versus LAGB was associated with higher risk of incident AUD symptoms (adjusted hazard ratio or AHR = 2.08 [95% CI: 1.51–2.85]), illicit drug use (AHR = 1.76 [95% CI: 1.07–2.90]) and SUD treatment (AHR = 3.56 [95% CI: 1.26–10.07]). **Conclusions:** Undergoing RYGB versus LAGB was associated with twice the risk of incident AUD symptoms. One-fifth of participants reported incident AUD symptoms within 5 years post-RYGB. AUD education, screening, evaluation, and treatment referral should be incorporated in pre-and postoperative care. (Surg Obes Relat Dis 2017;∎:00–00.) © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Roux-en-Y gastric bypass; Gastric band; Obese; Substance use; Disorder; Addiction; Abuse; Treatment

Bariatric surgery is the most effective treatment for severe obesity, resulting in substantial and durable weight reduction, and improvement in or remission of obesity-related co-morbidities [1]. However, evidence is mounting that Roux-en-Y gastric bypass (RYGB) increases the risk of developing an alcohol use disorder (AUD) [2-5]. Pharmacokinetic studies provide evidence that RYGB, but not laparoscopic adjustable gastric band (LAGB), is associated with higher peak blood alcohol concentration, which is reached more quickly compared with presurgery status or nonsurgical controls [2,5]. Additionally, rodent models suggest that RYGB increases alcohol reward sensitivity via a neurobiological mechanism, independent of changes in alcohol absorption [2,5]. Hypothesized pathways include changes to the ghrelin system and altered genetic expression in regions of the brain associated with reward circuitry [2,5].

Studies utilizing medical records have documented over-146 147 representation of prior bariatric surgery, or specifically RYGB, among adults in substance use disorder (SUD) 148 treatment programs [2,5,6]. However, findings from longi-149 tudinal studies of AUD-related outcomes before and after 150 bariatric surgery are inconsistent [3-5], and few studies 151 152 have long-term follow-up or evaluation of nonalcohol SUD [3,4], such that we have little understanding of whether the 153 risk of AUD or nonalcohol SUD changes over time and the 154 proportion of postsurgical patients that are ultimately 155 affected. Recent literature reviews of AUD or SUD and 156 bariatric surgery concluded there is a need for large, 157 prospective, longitudinal studies that extend beyond 158 2 years, separate alcohol from other drug use, use stand-159 ardized assessments, account for type of bariatric surgical 160 procedure and identify risk factors for development of 161 postsurgery AUD [3-5]. This study expands our prior work 162 [7] and addresses these gaps in the literature by evaluating 163 alcohol consumption, AUD symptoms, illicit drug use, and 164 SUD treatment for 7 years after RYGB and LAGB, and 165

identifying factors associated with incident SUD-related 167 outcomes. 168

166

170

171

172

173

Materials and methods

Design and patients

174 The Longitudinal Assessment of Bariatric Surgery-2 175 (LABS-2) study is a prospective observational cohort study 176 of patients at least 18 years old undergoing a first bariatric 177 surgical procedure as clinical care by participating surgeons 178 at ten hospitals from 6 clinical centers throughout the 179 United States [8]. LABS-2 had a target sample size of 180 2400 participants based on anticipated loss to follow-up 181 of $\leq 25\%$ and the desire to detect small effect sizes (e.g., 182 odds ratios of at least 2.0 for categorical outcomes) with 183 90% power. Patients were recruited by clinical research 184 investigators and their research coordinators between 185 February 2006 and February 2009. The institutional review 186 board at each center approved the protocol, and participants 187 gave written informed consent. The study is registered at 188 ClinicalTrials.gov (NCT00465829).

189 Baseline assessments were conducted by research staff 190 independent of clinical care after clearance for surgery [9]. 191 Criteria for surgery eligibility differed by site and may have 192 included screening for psychiatric disorders, including SUD 193 [10,11]. Participants were informed that their responses 194 were confidential, although informed consent specified that 195 investigators could take steps to prevent serious harm. 196 When participants reported having at least 5 drinks on a 197 typical drinking day or illicit drug use, a safety protocol was 198 triggered to assess the need for referral. Annual follow-up 199 assessments were conducted within 6 months of the surgery 200 anniversary date for 7 years or until January 31, 2015, 201 whichever came first. Participants included in this report 202 completed SUD-related measures at baseline and at least

Download English Version:

https://daneshyari.com/en/article/5661652

Download Persian Version:

https://daneshyari.com/article/5661652

Daneshyari.com